GlassScriptPhysician profile
Rhonda J Pomerantz
NPI 1164456448
$3,756.84
in general payments reported to CMS, 2019-2025
28 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $442 · 2021: $706 · 2022: $735 · 2023: $473 · 2024: $504 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $748.46 | 2019-2025 | |
| Incyte Corporation | $472.30 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $326.33 | 2023-2025 | Zoryve |
| Amgen INC. | $277.02 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $231.94 | 2019-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $205.79 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $177.22 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $165.16 | 2020-2025 | Cabtreo, Jublia, Siliq |
| Dermavant Sciences, INC. | $132.03 | 2022-2024 | Vtama |
| Almirall LLC | $130.76 | 2019-2022 | |
| Celgene Corporation | $116.23 | 2019 | |
| Sun Pharmaceutical Industries INC. | $100.58 | 2021-2025 | Absorica Ld, Winlevi |
| Sebela Pharmaceuticals INC. | $87.16 | 2022-2023 | Naftin, Pramosone |
| Epi Health, LLC | $80.80 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $80.59 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43.67 | 2021-2022 | |
| Genzyme Corporation | $42.67 | 2022 | |
| Sandoz INC. | $42.28 | 2020-2021 | |
| Allergan, INC. | $41.28 | 2021 | |
| Dermira, INC. | $40.79 | 2020 | |
| Journey Medical Corporation | $33.70 | 2020-2022 | |
| Lilly USA, LLC | $31.04 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.34 | 2022 | |
| Janssen Biotech, INC. | $26.98 | 2023 | Tremfya |
| Organon LLC | $25.88 | 2025 | |
| Abbvie INC. | $23.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.44 | 2024 | |
| Cipher Pharmaceuticals US LLC | $21.09 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Pomerantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.